**Current Funding Opportunities – August 13th, 2014**

**Below are Grant Opportunities from:**

**Alzheimer’s Association**

**Alzheimer’s Drug Discovery Foundation**

**American Brain Foundation & the American Academy of Neurology**

**BrightFocus Foundation**

**National Institutes of Health (**[**NIH**](http://www.nih.gov/)**)**

**To see more information on the opportunity please click on the link below. If you are interested in applying, please contact Katy Gilbert:** [katy.gilbert@bannerhealth.com](mailto:katy.gilbert@bannerhealth.com)

**AGING RESEARCH**

**Single Cell Studies in Aging Research (R01 & R21)**

**National Institutes of Health (**[**NIH**](http://www.nih.gov/)**)**

<http://grants.nih.gov/grants/guide/pa-files/PA-11-320.html>

<http://grants.nih.gov/grants/guide/pa-files/PA-11-321.html>

**Funding Amount:**

**R01:** Application budgets are not limited, but need to reflect actual needs of the proposed project.

**R21**: Application budgets are limited to $275,000 Direct Cost for 2 years, but need to reflect actual needs of the proposed project with no more than $200,000 in direct costs allowed in any single year. Scope of the proposed project should determine the project period. The maximum period is 2 years.

**Letter of Intent Due:** Not Applicable

**Application Deadline**:**R01 & R21**: *New*: October 16, 2014; *Renewal, Resubmission, Revision:* November 16, 2014

**Objective:**

**R01:** This FOA issued by the National Institute on Aging (NIA), National Institutes of Health, encourages grant applications from institutions/organizations that propose to develop research on single cell biology to enhance the understanding of the mechanisms of normal aging and of age-related diseases.  Applications using -omics technologies, imaging, optofluidic platforms, mass spectroscopy, whole genome sequencing, and other tools and technologies at the single cell level are encouraged since it is expected that the single cell approach will improve the determination of unique and biologically significant properties of tissues and organs during the aging process.

Although we know that cells are heterogeneous, for example they might be at different stages in the cell cycle or at different stages in tumor progression, most contemporary studies use population of cells, thus providing a limited average view of cellular and tissue function.  This is due mainly to the lack of tools to study single cells.  This is now changing.  Advances in technology have made more single cell studies feasible and will convert cellular heterogeneity from a source of noise to a source of new discoveries.

**R21:** The primary aim for this Funding Opportunity Announcement (FOA) is to encourage the submission of research projects that would advance biomedical research at the single cell level, facilitating the identification of molecular and cellular markers of normal aging and in disease progression during aging; and to advance the understanding of the impact of cellular heterogeneity during aging across a broad range of cell types and disease states.

NIA would welcome new directions in aging research that make use of single cell approaches in multi-cellular model systems.  Areas of interest and appropriate topics in aging research include but are not limited to:

* characterization of cellular heterogeneity in aging tissues,
* understanding the response of individual cells to tissue damage and repair during aging,
* characterization of single molecule and sub-cellular organelle dynamics in aged tissues,
* identifying changes in tissue structure/function during normal aging and in age-related diseases,
* understanding cellular communication and cell-cell interactions in aged tissues,
* determination of cellular complexity in an old tissue or organ,
* assessing the natural history of cells in the same tissue/organ/animal.

Investigators interested in developing new tools and technologies for single cell analyses should inquire with other NIH Institutes and Centers about their interest in supporting such research activities.  It is expected that many of the projects submitted in response to this FOA will be collaborative efforts between and among investigators with different perspectives and backgrounds and with significant interests and expertise in the tools and technologies for single cell analyses and expertise in aging research.

**Grant Application Submission Instructions:**

**R01:** <http://grants.nih.gov/grants/guide/pa-files/PA-11-320.html#_Section_IV._Application_1>

**R21:** <http://grants.nih.gov/grants/guide/pa-files/PA-11-321.html#_Section_IV._Application_1>

**T1 Translational Research: Novel interventions for prevention and treatment of age-related conditions (R21)**

**National Institutes of Health (**[**NIH**](http://www.nih.gov/)**)**

<http://grants.nih.gov/grants/guide/pa-files/PAS-11-280.html>

**Funding Amount:** Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

**Letter of Intent Due:** Not Applicable

**Application Deadline**: *New*: October 16, 2014; *Renewal, Resubmission, Revision:* November 16, 2014

**Objective:** This funding opportunity announcement (FOA) encourages exploratory/developmental R21 research projects to accelerate the pace of development of novel therapeutics involving biologics, pharmacological and non-pharmacological approaches for preventing and treating key health issues affecting the elderly.   For the purposes of this FOA, T1 translational research on aging is defined as the application of basic and clinical biomedical findings towards the development of new strategies for prevention and treatment of age-related pathologies. For projects proposing basic research that is being conducted in animal models, the potential to treat a clinical age-related pathology must be clearly stated in the proposal.  Direct relevance of the data to a clinical aging condition must be established and clearly stated in the application.

**Grant Application Submission Instructions:**

<http://grants.nih.gov/grants/guide/pa-files/PAS-11-280.html#_Section_IV._Application_1>

**Paul B. Beeson Clinical Scientist Development Award in Aging (K08)**

**National Institutes of Health (**[**NIH**](http://www.nih.gov/)**)**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-15-016.html>

**Funding Amount:** Award budgets are composed of salary and other program-related expenses

**Letter of Intent Due:** October 7, 2014

**Application Deadline**: November 7, 2014

**Objective:** The objective of the NIH Mentored Clinical Scientist Research Career Development Award (K08) program is to provide salary and research support for a sustained period of “protected time” (3-5 years) to support didactic study and/or mentored research for individuals with clinical doctoral degrees (e.g., M.D., D.D.S., D.M.D., D.O., D.C., O.D., N.D., D.V.M., Pharm.D., or Ph.D. in clinical disciplines).

The K08 provides support for an intensive, mentored research career development experience in biomedical or behavioral research in aging and geriatrics, including translational research. For the purpose of this award, translational research is defined as application of basic research discoveries toward the diagnosis, management, and prevention of human disease. Individuals with a clinical doctoral degree interested in pursuing a career in patient-oriented research should refer to the companion FOA, [RFA-AG-15-017](http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-15-017.html) "Paul B. Beeson Patient-Oriented Research Career Development Award in Aging (K23)".

The K08 award may be used by candidates (the applicant, i.e., PD/PI) with different levels of prior research training and at different stages in their career development. For example, a candidate with limited experience in a given field of research may use an award to support a career development experience that includes a designated period of didactic training followed by a period of closely supervised research experience. A candidate with previous research experience and training may not require extensive additional didactic preparation, and may use an award to support a career development experience that focuses on an intensive, supervised research experience.

The BCDA provides support to clinically trained faculty members in strong research environments to enable them to gain skills and experience in clinically relevant aging research and to establish an independent program of research in these fields. K08 candidates must identify mentors who are senior researchers in aging and/or geriatrics and who agree to commit time to supervising and guiding the candidates during the period of the award.

**Grant Application Submission Instructions:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-15-016.html#_Section_IV._Application>

**Paul B. Beeson Patient Patient-Oriented Research Career Development Award in Aging (K23)**

**National Institutes of Health (**[**NIH**](http://www.nih.gov/)**)**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-15-017.html>

**Funding Amount:** Award budgets are composed of salary and other program-related expenses.

**Letter of Intent Due:** October 7, 2014

**Application Deadline**: November 7, 2014

**Objective:** The objective of the NIH Mentored Patient-Oriented Research Career Development Award (K23) program is to provide salary and research support for a sustained period of “protected time” (3-5 years) to ensure a future cadre of well-trained scientists working in Patient-Oriented Research (POR). The K23 award is expected to help research-oriented clinicians to develop research skills and gain experience in advanced methods and experimental approaches needed to become an independent investigator conducting POR. Clinicians investigating clinically relevant research, broadly defined as  work in the basic sciences including animal models of aging, or the use of secondary data analyses where there is apparent clinical relevance should refer to the companion FOA, [RFA-AG-15-016](http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-15-016.html) "Paul B. Beeson Clinical Scientist Development Award in Aging (K08)".

For the purposes of the K23 award, Patient-Oriented Research is defined as research conducted with human subjects (including measures of cognition or research using material of human origin such as blood and tissue samples) for whom an investigator directly interacts with human subjects. This area of research includes: 1) mechanisms of human disease; 2) therapeutic interventions; 3) clinical trials; and 4) the development of new technologies. Studies falling under Exemption 4 for human subjects research are not included in this definition.

Other examples include but are not limited to:

* Transplantation in older patients;
* Outcomes of the older patients in hospital, acute and long term care settings;
* Multimorbitity in older patients: treatment and the disease burden
* Studies of prevention approaches tailored to older adults
* Studies of well-being in older adults in informal and formal care settings

**Grant Application Submission Instructions:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-15-017.html#_Section_IV._Application>

**Nathan Shock Centers of Excellence in Basic Biology of Aging (P30)**

**National Institutes of Health (**[**NIH**](http://www.nih.gov/)**)**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-15-005.html>

**Funding Amount:** Application budgets are limited to no more than $600,000 per year in Direct Costs, but need to reflect the actual needs of the proposed project. Awards are expected to be made for 5 years.

**Letter of Intent Due:** September 28, 2014

**Application Deadline**: October 28, 2014

**Objective:** This Funding Opportunity Announcement (FOA) invites applications for Centers, known as Nathan Shock Centers of Excellence in Basic Biology of Aging (NSC). These Center grants will provide funding for leadership, training, and research activities that will increase the dissemination of scientific knowledge in the research areas supported by the NIA's Division of Aging Biology, which include but are not limited to genetics, cell biology of aging, and physiology of aging  (<http://www.nia.nih.gov/research/dab>).  NSC awards are intended for institutions that can demonstrate a substantial  investment in and commitment to ongoing and future high-impact research on the basic biology of aging.

NIA expects that NSC awardees will:

* Provide intellectual leadership and innovation;
* Develop and/or support innovative cores that are uniquely focused on the needs of the field;
* Provide research career development for future leaders in basic aging research;
* Collaborate substantially with other NSCs, including conferences and outreach activities;
* Serve as a source of advice and collaboration to other investigators locally and on a large-scale regarding technology, methodology, analysis, or other expertise; and
* Leverage institutional resources, including other NIH-supported programs and centers, to maximize efficiency in achieving the NSC's aims.

These grants are not intended to directly support the independent research of the Program Director/Principal Investigator (PD/PI) or the Core Directors, and are not intended to support clinical research/clinical trials, or research on neurobiology of aging.

**Grant Application Submission Instructions:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-15-005.html#_Section_IV._Application_1>

**ALZHEIMER’S RESEARCH**

**New Investigator Research Grant**

**Alzheimer’s Association**

<http://www.alz.org/research/downloads/New-Investigator-Program-3-pages.pdf>

**Funding Amount:** Each total award is limited to $100,000 (direct and indirect costs) for up to two years. Requests in any given year may not exceed $60,000 (direct and indirect costs). Indirect costs are capped at 10 percent (rent for laboratory/office space is expected to be covered by indirect costs paid to the institution).

**Letter of Intent Due:** September 24, 2014

**Application Deadline**: October 30, 2014

**Objective:** The competition, formerly known as the Pilot Research Grant Program, has become the New Investigator Research Grant Program. This change is designed to reinforce the historical emphasis of this competition—to fund

investigators who are less than 10 years past their doctoral degree. The purpose of this program is to provide newly independent investigators with funding that will allow them to develop preliminary or pilot data, to test procedures and to develop hypotheses. The intent is to support early-career development that will lay the groundwork for future research grant applications to the National Institutes of Health, National Science Foundation and other funding agencies and groups, including future proposals to the Alzheimer's Association. All NIRG applications must target defined areas of focus for fiscal year 2015 to be considered responsive to the program announcement (see Section II). The Alzheimer‘s Association recognizes the need to increase the number of scientists from underrepresented groups in the research enterprise. Young scientists from these groups are encouraged to apply.

**Grant Application Submission Instructions:** <http://www.alz.org/research/alzheimers_grants/grant_application_process.asp#applying>

**New Investigator Research Grant to Promote Diversity**

**Alzheimer’s Association**

<http://www.alz.org/research/downloads/New-Investigator-Diversity-3-pages.pdf>

**Funding Amount:** Each NIRGD award is limited to $100,000 (direct and indirect costs) for up to two years. Requests in any given year may not exceed $60,000 (direct and indirect costs). Indirect costs are capped at 10 percent (rent for laboratory/office space is expected to be covered by indirect costs paid to the institution).

**Letter of Intent Due:** September 24, 2014

**Application Deadline**: October 30, 2014

**Objective:** The New Investigator Research Grant to Promote Diversity in Alzheimer‘s research is a two-year award to investigators who are currently underrepresented at academic institutions in Alzheimer‘s or related dementias research.

The objective of this award is to increase the number of highly trained investigators from diverse backgrounds whose basic, clinical and social/behavioral research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to Alzheimer‘s and related dementias in general and in health disparities

populations. The Alzheimer‘s Association recognizes the need to increase the number of underrepresented scientists participating in biomedical and behavioral research. The Association anticipates that by providing these research opportunities, the number of underrepresented scientists entering and remaining in biomedical research careers in

Alzheimer‘s disease will increase.

**Grant Application Submission Instructions:** <http://www.alz.org/research/alzheimers_grants/grant_application_process.asp#applying>

**Mentored New Investigator Research Grant to Promote Diversity**

**Alzheimer’s Association**

<http://www.alz.org/research/downloads/Mentored-New-Investigator-4-pages.pdf>

**Funding Amount:** The Alzheimer‘s Association anticipates funding 1-2 NIRGD/ MNIRGD awards under this competition. Each MNIRGD award is limited to $170,000. A total of $150,000 will be awarded for costs related to the proposed research for up to three years (direct and indirect costs). Requests in any given year may not exceed $60,000

(direct and indirect costs). Indirect costs are capped at 10 percent (rent for laboratory/office space is expected to be covered by indirect costs paid to the institution). The Principal Investigator must commit to a 50 percent effort toward the proposed project over the funding period.

The remaining funds, $10,000 to the applicant and $10,000 to the primary mentor, will be awarded upon successful completion of the program. These additional funds are to be applied to sustaining ongoing research in the Alzheimer‘s field and will be awarded through the applicant‘s and mentor‘s institutions.

**Letter of Intent Due:** September 24, 2014

**Application Deadline**: October 30, 2014

**Objective:** The Mentored New Investigator Research Grant to Promote Diversity is a three-year award intended to be a research-based and mentoring investment to help close disparities between diverse and non-diverse investigator populations. The Alzheimer‘s Association feels strongly that the mentoring and involvement of diverse

researchers in independently funded Alzheimer‘s research is a pressing need. The MNIRGD is intended to enhance the capacity of diverse and non-diverse scientists to conduct basic, clinical and social/behavioral research.

***The MNIRGD competition has the following general requirements:***

* Foster mentoring relationships between experienced researchers and those not

previously funded or considered newly independent investigators (under 10 years post

degree);

* Increase the presence of scientists from diverse backgrounds who are conducting

research on Alzheimer‘s and related dementias;

* Enhance the research skills and scientific visibility of junior faculty members from

diverse backgrounds;

* Support mentoring relationships that will establish enduring research careers of diverse

scientists.

**Grant Application Submission Instructions:**

<http://www.alz.org/research/alzheimers_grants/grant_application_process.asp#applying>

**Alzheimer’s Disease Research: Standard Awards**

**BrightFocus Foundation**

<http://www.brightfocus.org/research/apply/openawards.html>

**Funding Amount:** $250,000 for three years

**Letter of Intent Due:** Not Applicable

**Application Deadline**: October 14, 2014

**Objective:** The standard award provides significant funding for researchers who have already generated some amount of preliminary data, but often still require significant progress before they can apply to governmental or industrial funding agencies.

**Grant Application Submission Instructions:** <http://www.brightfocus.org/research/apply/main.html>

**Alzheimer’s Disease Research: Postdoctoral Fellowship Awards**

**BrightFocus Foundation**

<http://www.brightfocus.org/research/apply/openawards.html>

**Funding Amount:** $100,000 for two years

**Letter of Intent Due:** Not Applicable

**Application Deadline**: October 14, 2014

**Objective:** Postdoctoral fellowship awards are intended for young researchers in their final stages of mentored training. These awards are meant to fund projects in an established laboratory that will serve as the basis for the applicant's own independent research career.

**Grant Application Submission Instructions:** <http://www.brightfocus.org/research/apply/main.html>

**Biomarker-Based Target Engagement Studies to Support Clinical Development of Novel Therapeutics for Alzheimer’s Disease**

**Alzheimer’s Drug Discovery Foundation**

<http://alzdiscovery.org/assets/content/static/ADDF-ADCS_RFP_FINAL.pdf>

**Funding Amount:** ADDF and ADCS will provide funding and resources to one or more clinical trials meeting the specifications described above. In addition to funding, ADCS will contribute resources and infrastructure for data management, quality control, and statistics support. ADCS will also offer access to unique biomarker assays including the SILK technology, if appropriate.

**Letter of Intent Due:** Submission of a Letter of Intent (LOI) through the ADDF’s website (www.alzdiscovery.org) is required to initiate the application process.

**Application Deadline**: September 5, 2014

**Objective:** The Alzheimer’s Drug Discovery Foundation (ADDF) and the Alzheimer’s Disease Cooperative Study (ADCS) are collaborating to support pilot biomarker-based clinical trial(s) of novel therapeutic(s) for Alzheimer’s disease. Therapeutics for which target engagement can be directly assessed in humans using serial cerebrospinal fluid sampling are of highest priority. The proposed study can augment an existing study or be a new pilot clinical trial.

**Grant Application Submission Instructions:**

<http://alzdiscovery.org/assets/content/static/ADDF-ADCS_RFP_FINAL.pdf>

**Accelerating Drug Discovery for Frontotemporal Degneration**

**Alzheimer’s Drug Discovery Foundation**

<http://alzdiscovery.org/assets/content/static/2014_ADDF-AFTD_FTD_RFP.pdf>

**Funding Amount:**  ADDF/AFTD will provide grants for one-year duration (up to $150,000 each) with the possibility of follow-on funding.

**Letter of Intent Due by: August 22, 2014**

**Application Deadline**: September 5, 2014

**Objective:**

Research investigating the pathologic mechanisms underlying frontotemporal degeneration (FTD) and related disorders is advancing, creating new potential targets for drug discovery. The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate and support drug discovery for FTD and related disorders through this Request for Proposals (RFP).

**Priority areas for this program include:**

* *Development of clinical, biochemical, or neuroimaging biomarkers to accelerate drug development and early diagnosis*
* *High throughput screening in novel cellular assays relevant to FTD*
* *Identification and in vitro testing of potentially disease modifying compounds or biologics, including medicinal chemistry refinement, ADME, toxicology, pharmacokinetics, and pharmacodynamics studies*
* *Testing of lead compounds or biologics in a relevant model for preclinical proof of concept*

**Grant Application Submission Instructions:** <http://alzdiscovery.org/assets/content/static/2014_ADDF-AFTD_FTD_RFP.pdf>

**Immune and Inflammatory Mechanisms in Alzheimer’s Disease (R01)**

**National Institutes of Health (**[**NIH**](http://www.nih.gov/)**)**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-15-018.html>

**Funding Amount:** Application budgets need to reflect the actual needs of the proposed project and should be limited to no more than $500,000 direct cost per year. The maximum project period is 5 years.

**Letter of Intent Due:** December 29, 2014

**Application Deadline**: January 29, 2014

**Objective:** The goal of this FOA is to establish the immune and inflammatory mechanisms contributing to or mediating the development and progression of AD.  A comprehensive and integrative characterization of the brain innate immune system, its crosstalk with the systemic immune system, and its changes with age will help define the mechanisms underlying the shift from normal aging to pathological processes in the etiology of AD.  Such characterization should include studies on the genetic, epigenetic, molecular and cellular underpinnings of the physiological immune and inflammatory responses in AD. Development of cell or functional markers of, and tools to manipulate or track peripheral and CNS immune cells would help establish the role of distinct immune cells in AD. The contribution of aging processes in the brain (e.g. microglial senescence) and in peripheral immune/inflammatory networks (e.g. chronic low level inflammation) in the initiation and/or progression of AD should be considered.   Applicants to this FOA must emphasize the multidisciplinary and integrative research approaches taken to identify the cell networks, mediators and pathways of the brain and systemic immune and inflammatory systems that influence the development and progression of AD.

**Grant Application Submission Instructions:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-15-018.html#_Section_IV._Application_1>

**NEUROLOGY RESEARCH**

**Practice Research Training Fellowship**

**The American Brain Foundation / The American Academy of Neurology**

<https://www.aan.com/uploadedFiles/Website_Library_Assets/Documents/5.Research_and_Awards/1.Awards_and_Scholarships/2.Clinical_Research_Fellowships/2.Practice_Research_Training_Fellowships/2013%20Practice%20Research%20Training%20Fellowship.pdf>

**Funding Amount:** $55,000 per year for two years, plus $10,000 per year for tuition to support formal education in clinical research methodology at the applicant’s institution or elsewhere. Supplementation of the stipend with other grants or by the fellowship institution is permissible, but fellows may not accept other fellowships, similar awards,

or have another source of support for more than 50 percent of their research salary during the first year of an American Brain Foundation Clinical Research Training Fellowship.

**Letter of Intent Due:** Not Applicable

**Application Deadline**: October 1, 2014

**Objective:** The American Brain Foundation, the foundation of the American Academy of Neurology, is pleased to announce a two-year fellowship to support training in clinical practice research, which is defined as “clinical research that evaluates translation of evidence into best clinical practice.” This may include evaluation of health services, quality of care, implementation of proven therapies, physician performance, or patient adherence. It is intended to create unique training opportunities, previously difficult to access for neurologists.

**Grant Application Submission Instructions:** <https://www.aan.com/research-and-awards/research-training-fellowships/>

**TRANSFORMATIVE RESEARCH**

**NIH Transformative Research Awards (R01)**

**National Institutes of Health (**[**NIH**](http://www.nih.gov/)**)**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-14-003.html>

**Funding Amount:** Application budgets are not limited but must reflect the actual needs of the proposed research. The maximum project period is five years.

**Letter of Intent Due:** September 10, 2014

**Application Deadline**: October 10, 2014

**Objective:** The goal of the NIH Transformative Research Awards initiative is to provide support for collaborative investigative teams or individual scientists who propose transformative research projects, which, if successful, would have a major impact in a broad area of biomedical or behavioral research. To be considered transformative, projects must have the potential to create or overturn fundamental scientific paradigms through the use of novel approaches, to transform the way research is conducted through the development of novel tools or technologies, or to lead to major improvements in health through the development of highly innovative therapies, diagnostic tools, or preventive strategies. Consistent with this focus, applications supported under the Transformative Research Awards initiative will reflect ideas substantially different from mainstream concepts.

Several key features of this FOA have been designed to emphasize to applicants and peer reviewers that these applications are very different from conventional, investigator-initiated research awards. The application format and requirements for explicitly addressing specific issues, focuses attention on the importance of the problem, the novelty of the hypothesis and/or the proposed methodology, and the magnitude of the potential impact rather than on experimental details. Reviewers will be instructed to emphasize significance and innovation in their evaluations, and these criteria will be the primary basis for funding decisions.  These features are intended to steer applicants and reviewers, at each step of the process, toward the goal of this initiative, which is to solicit and fund unusually bold and potentially transformative research.

Projects in any area of NIH interest, including basic, clinical, translational and behavioral studies, are encouraged and will be considered responsive to this FOA. Though technical and conceptual risks are expected in highly innovative projects, clinical research also must address the potential risk to human subjects. Clinical researchers are encouraged to submit applications as long as rigorous assessment of participant risk/benefit ratios compellingly indicates the ratio to be in favor of the potential benefit. Many of the advances in public health have been achieved through clinical trials, which necessarily involve some risk to participating human subjects.

**Grant Application Submission Instructions:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-14-003.html#_Section_IV._Application_1>